Results 161 to 170 of about 35,808 (310)
Delphi consensus: First‐line use of biologics and small molecules in hidradenitis suppurativa
Journal of the European Academy of Dermatology and Venereology, EarlyView.This Delphi Consensus study identified upgrade criteria for the use of biologics and small molecules as first‐line therapy in hidradenitis suppurativa (HS). European HS experts evaluated 16 clinical scenarios, voting on eligibility for therapy escalation.Georgios Nikolakis, Erkan Alpsoy, Florian Anzengruber, Matthias Augustin, Falk G. Bechara, Pierre‐André Becherel, Farida Benhadou, Vincenzo Bettoli, Joana Cabete, Raffaele Dante Caposiena Caro, Antonella Di Cesare, Giovanni Damiani, Valentina Dini, Evangelos J. Giamarellos‐Bourboulis, Krisztián Gáspár, Katalin Glasenhardt, Philippe Guillem, Ariela Hafner, Barbara Horvath, John R. Ingram, Vaiva Jarienè, Gregor B. E. Jemec, Alexander Katoulis, Natalia Kirsten, Georgios Kokolakis, Piotr K. Krajewski, Aikaterini I. Liakou, Flavia Manzo Margiotta, Angelo V. Marzano, Antonio Martorell, Lukasz Matusiak, Dillon Mintoff, Alejandro Molina Leyva, Andreas Pinter, Anna Pirogova, Maurizio Podda, Francesca Prignano, Jorge Romani, Marco Romanelli, Elia Rosi, Samed Sahin, Ditte M. L. Saunte, Sylke Schneider‐Burrus, Mariano Suppa, Jacek Szepietowski, Andrea Szegedi, Simon Francis Thomsen, Thrasyvoulos Tzellos, Anastasia Trigoni, Hessel H. Van Der Zee, Kelsey Van Straalen, Skaidra Valiukevičiene, Eva Vilarrasa, Esther von Stebut, Christos C. Zouboulis +54 morewiley +1 more sourceFamily quality‐of‐life burden in chronic spontaneous urticaria: A multicentre study
Journal of the European Academy of Dermatology and Venereology, EarlyView.Poor control of chronic spontaneous urticaria (CSU) significantly worsens family members' quality of life, especially in emotional, physical, and social domains. Higher disease severity was linked to increased caregiving burden and household expenditures, highlighting the need for family‐centred CSU care and support across diverse global populations ...Beatrice Martinez Zugaib Abdalla, Roberta Fachini Jardim Criado, Kanokvalai Kulthanan, Emek Kocatürk, Ivan Cherrez‐Ojeda, Ana Maria Giménez‐Arnau, Marcus Maurer, Luis Felipe Ensina, Jonathan A. Bernstein, Michihiro Hide, Sergio Duarte Dortas Junior, Solange Oliveira Rodrigues Valle, Gabriela Dias, Paraskevi Xepapadak, Priyanshi Dangi, Indrashis Podder, Vesna Trajkova, Natasa Teovska Mitrevska, Iman Hamed Nasr, Bushra Al Hinai, Joanna Bartosińska, Dorota Krasowska, Paulina Szczepanik‐Kułak, Hilal Gungor, Deniz Ozceker, Kübra Çiçek, Esen Özkaya, Yasemin Erdem, Mücahit Ergün, Mustafa Tosun, Rabia Oztas Kara, Jie Li, Anastasia Allenova, Paulo Ricardo Criado +33 morewiley +1 more sourceEuropean S2k guidelines on management of autoimmune blistering diseases in children and adolescents
Journal of the European Academy of Dermatology and Venereology, EarlyView.Autoimmune blistering disorders (AIBDs) in children are rare, challenging to diagnose and treat and often require immunosuppressants. Until now, no paediatric care guidelines existed. The EADV Task Force for AIBDs has developed the consensus‐based recommendations, enabling physicians to adopt a uniform, tailored treatment strategy to improve outcomes ...A. Nanda, B. Tedbirt, C. Bodemer, M. C. Bolling, M. El Hachem, M. Nikolić, E. Benton, M. Caproni, D. De, D. Didona, K. Drenovska, M. Goebeler, M. Hertl, B. Horváth, M. Kasperkiewicz, D. Kiritsi, M. Larralde, A. V. Marzano, J. Meijer, D. F. Murrell, J. Powell, E. Sprecher, N. S. Chandran, M. M. Tomayko, S. Uzun, N. van Beek, H. Ott, A. Patsatsi, A. Torrelo, A. Welfringer‐Morin, E. Schmidt, P. Joly +31 morewiley +1 more sourceBritish Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen-ultraviolet A therapy 2015 [PDF]
, 2016 Abel EA, Berg M, Berg M, Bhatnagar A, Bilsland D, Bjellerup M, Calzavara‐Pinton PG, Chen X, Cox AJ, Deleu H, Diffey BL, Freeman K, George SA, Gilchrest BA, Grattan CE, Hannuksela M, Hönigsmann H, Jansén CT, Jansén CT, Jeanmougin M, Joint Formulary Committee, Kao CL, Kivanc MT, Lassus A, Leonard F, LeVine MJ, Lindelöf B, Maravić N, Margolis D, Marguery MC, Marsland AM, Mastalier U, Mathews‐Roth MM, McFadden N, McGeorge BC, Molin L, Morison WL, Neumann NJ, Norris PG, Park YM, Pirner K, Pothiawala SZ, Reymond JL, Roelandts R, Roelandts R, Roelandts R, Roenigk HH, Ros AM, Ros AM, Rosén K, Rosén K, Rosén K, Rübben A, Sheehan‐Dare RA, Stadler R, Stern RS, Takashima A, Tegner E, Tegner E, Thomsen K, Turjanmaa K, Viander M, Vázquez‐López F, Weelden H, Wennersten G, Wilkinson JD +65 morecore +2 more sources